Company Overview of Asmacure Ltée
Asmacure Ltée, a clinical-stage biopharmaceutical company, focuses on the development of proprietary molecules that target cholinergic receptors for the treatment of inflammation (primarily pulmonary airway diseases). It develops ASM-024 for the treatment of moderate asthma and chronic obstructive pulmonary disease with a dry powder for inhalation formulation. The company was founded in 2002 and is based in Quebec City, Canada. As of August 19, 2015, Asmacure Ltée operates as a subsidiary of Odan Laboratories Ltd.
2600, Boulevard Laurier
Quebec City, QC G1V 4W2
Founded in 2002
Key Executives for Asmacure Ltée
Founder, Chief Medical Officer and Director
Co-Founder and Vice President of Pre-Clinical Research & Development
Vice President of Finance and Administration
Vice President of Corporate Affairs & Planning
Compensation as of Fiscal Year 2015.
Asmacure Ltée Key Developments
Asmacure Ltee Announces Clinical Update for Asmacure Ltee in Two Phase 2 Trials
Dec 17 13
Asmacure Ltee announced that the company has completed dosing in a Phase 2 trial evaluating its lead compound, ASM-024, in moderate asthma patients, with data anticipated in the first quarter of 2014. The company also has begun patient enrollment in a Phase 2 trial of ASM-024 in patients with moderate and severe chronic obstructive pulmonary disease (COPD). The recently completed Phase 2 asthma trial is a randomized, double-blind, placebo-controlled study with a primary outcome designed to evaluate the safety, tolerability, and dose selection of the ASM-024 dry powder for inhalation (DPI) dosage form in 15 patients with moderate asthma. The Phase 2 COPD trial is a randomized, double-blind, placebo-controlled, two-way crossover study designed to evaluate clinical outcomes and safety of the ASM-024 DPI dosage form in approximately 15 patients with GOLD 2 and GOLD 3 COPD. Each patient will be dosed for two weeks in each treatment period of the two-way crossover design. Data from this trial are expected in the third quarter of 2014. ASM-024's novel multi-functional mechanism of action involves effects at the nicotinic and muscarinic levels. Previous studies have shown that ASM-024 solution formulation induced smooth muscle relaxation as well as anti-inflammatory and bronchodilating effects, which may address an unmet medical need as an adjunctive treatment with current standard of care in patients with moderate to severe asthma and COPD. The precise mechanisms of action of ASM-024 continue to be studied.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 19, 2015
Most Searched Private Companies
Sponsored Financial Commentaries